| 2/25/2014 | CVLM | ViroPharma gets no tenders in offer for 2% convertibles after buyout
|
| 1/24/2014 | CVLM | ViroPharma tenders for any and all 2% convertibles after acquisition
|
| 11/14/2013 | CV | ViroPharma's 2% notes convertible in connection with merger agreement
|
| 11/11/2013 | CV | Market Commentary: Holiday weighs on convertibles liquidity; ViroPharma boosted by Shire acquisition news
|
| 9/13/2013 | CV | Market Commentary: ViroPharma jumps on takeout chatter; new Protalix moves up outright; GSV Capital gains
|
| 8/1/2013 | CV | Market Commentary: ViroPharma convertibles add on hedge; Trinity contracts; ArcelorMittal mandatories flat
|
| 6/17/2013 | CV | Market Commentary: Planned Extra Space reoffered, talk revised; Weyerhaeuser launches deal; Medivation eyed
|
| 11/15/2011 | CV | Market Commentary: Goldcorp active; Meritor, ViroPharma shed about a point on swap; Air Lease deal revised
|
| 9/15/2011 | CVLM | ViroPharma may buy back another $200 million stock or 2% convertibles
|
| 3/9/2011 | CVLM | ViroPharma may buy back some 2% convertibles via $150 million program
|
| 1/11/2011 | CV | Market Commentary: Lennar improves on hedge; ViroPharma adds 0.25 point dollar neutral; Sotheby's cheaper
|
| 10/22/2010 | CV | Market Commentary: SanDisk higher after earnings; ViroPharma up 0.5 point on swap; new Cubist moves above par
|
| 7/27/2010 | CV | Market Commentary: Gilead opens higher, comes in; Onyx, ViroPharma in trade; AGCO in line; A&P bounces around
|
| 6/18/2009 | BWCV | ViroPharma says company well positioned for future acquisitions
|
| 3/24/2009 | CV | ViroPharma buys back $45 million of convertibles due 2017
|
| 2/9/2009 | CV | Market Commentary: Convertibles little changed ahead of bank plan; Newmont weakens; ViroPharma plunges outright
|
| 3/26/2007 | CV | ViroPharma greenshoe exercised, raising 2% convertibles to $250 million
|
| 3/21/2007 | CV | Market Commentary: Vornado on tap; Komag jumps in; SL Green, SBA only laggards on new deal train; Freeport up in gray
|
| 3/21/2007 | CV | New Issue: ViroPharma prices upsized $225 million 10-year senior notes at 2%, up 32.5%
|
| 3/20/2007 | CV | Market Commentary: Host Hotels up slightly on debut; ViroPharma, Pioneer lead, SBA, ProLogis dull in gray market
|
| 3/19/2007 | CV | ViroPharma files automatic shelf
|
| 3/19/2007 | CV | ViroPharma to price $200 million 10-year convertibles Tuesday, talked at 2%-2.5%, up 27.5%-32.5%
|
| 3/19/2007 | CV | Market Commentary: AtheroGenics falls; Host Hotels, Freeport-McMoran up in gray; ProLogis, ViroPharma, Pioneer plan deals
|
| 1/26/2006 | CV | Market Commentary: New issues mixed, NRG trades up, UAG flat; Juniper drops; DRS launches $300 million of convertibles
|
| 1/26/2006 | CV | ViroPharma calls $79 million 6% convertibles due 2007
|
| 7/5/2005 | BTCVPP | ViroPharma to convert 6% convertibles on July 12
|
| 6/20/2005 | BTCVPP | ViroPharma to automatically convert $18.75 million of 6% convertibles
|
| 6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
| 6/9/2005 | CV | Market Commentary: Calpine convertibles mixed after news whammy; market firms on fewer redemptions
|
| 6/2/2005 | CV | Market Commentary: Cephalon suffers in aftermarket; Joy Global pulled; Symmetricom at bat; Elan retreats on drug news
|
| 5/12/2005 | CV | Market Commentary: GM, Ford head renewed move south; Delta convertibles idle after 7.7s swapped for equity
|
| 5/11/2005 | CV | Market Commentary: Delta bankruptcy seen inevitable; GM, Ford weigh financials, IPG; KV Pharma slammed; Red Hat up
|
| 5/11/2005 | CV | ViroPharma buys back $29 million 6% convertibles
|
| 5/2/2005 | CV | Market Commentary: Corixa converts climb to par on takeover, other biotechs mixed; Calpine higher; Primus plunges
|
| 1/19/2005 | CV | Market Commentary: Alexion goes to 102; Antigenics sweetens terms; Charter exodus continues; auto, airline paper lower
|
| 1/19/2005 | CVPP | New Issue: ViroPharma stockholders approve exchange of notes; company to issue new 2009 notes
|
| 10/25/2004 | CV | Market Commentary: Armor overnighter slips in gray market; Isolagen, Option Care deals also emerge
|
| 10/18/2004 | CVPP | New Issue: ViroPharma sells $62.5 million 10% step-up senior bridge notes
|
| 10/18/2004 | CV | Market Commentary: Sirius convertibles up on Ford news; Elan active, edges up on Biogen buzz; CNet gains
|
| 8/24/2004 | CV | Market Commentary: Reliant gains on switching out of Calpine; CenterPoint easier; Delta better; ViroPharma gains
|
| 6/23/2004 | CV | Market Commentary: Calpine powered up by arbs; Matria gains; Nextel Partners soars; two new deals emerge
|
| 6/23/2004 | CV | ViroPharma pulls exchange
|
| 6/17/2004 | CV | ViroPharma fixes terms of exchange for convertibles
|
| 6/15/2004 | CV | ViroPharma extends exchange for convertibles
|
| 6/9/2004 | CV | ViroPharma fixes terms of exchange for convertibles
|
| 5/26/2004 | CV | ViroPharma amends exchange for convertibles
|
| 5/21/2004 | CV | ViroPharma sets pricing in convertibles exchange
|
| 3/22/2004 | CV | ViroPharma exchange runs through April 26
|
| 3/19/2004 | CV | ViroPharma plans exchange for 6% convertibles, to sell $25 million new convertibles
|
| 1/3/2003 | CV | ViroPharma buys back $45.1 million convertibles
|
| 4/5/2002 | CV | Salomon: Shrinking premiums, rising delta signal times to shift positions
|
| 3/20/2002 | CV | Market Commentary: Convertibles drop; PDLI joins ViroPharma, other biotechs in freefall
|
| 3/19/2002 | CV | Market Commentary: Convertibles tread water; Lucent, XM Satellite fall, ViroPharma halted
|
